Specifically, GIP agonism promotes lipolysis, while GCG agonism enhances substrate utilization and increases energy expenditure [9]
Focus particularly on protein intake, as this is the most commonly deficient macronutrient during Retatrutide treatment
Key findings: Prescribing trends Using a subset of real-world electronic health record (EHR) data from Truveta, Truveta Research identified people who were prescribed a GLP-1 RA between January 01, 2018 and September 30, 2024
The discovery of the incretin hormone GLP-1 and its subsequent studies led to a better understanding of its role in glycemic control and body weight regulation, as well as its potential use in clinical settings
Treatment not only suppressed the HFD-driven overexpression of lipogenic genes (e.g., Fasn , -22%
Continue working through the algorithm until the patients glucose is stabilized